Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic/R2

This article was originally published in The Gray Sheet

Executive Summary

Integration of R2 Technology's ImageChecker computer aided detection (CAD) technology with Hologic's Lorad Selenia amorphous-selenium, direct-capture full-field digital mammography system enabled under Sept. 26 collaboration agreement. The pact mirrors similar R2 relationships with digital mammography device makers Fischer Imaging and GE Medical Systems (1"The Gray Sheet" Sept. 23, 2002, p. 26). A PMA supplement for the Selenia is pending at FDA. Hologic and R2 will seek additional approvals for the integrated system...

You may also be interested in...



Fischer, R2 PMA Supplements Aimed At SenoScan/ImageChecker Combo

Fischer Imaging and R2 Technology are preparing separate PMA supplements to allow marketing of SenoScan full field digital mammography systems integrating R2's ImageChecker computer aided detection (CAD) technology

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief. 

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel